Chester Oddis
Rheumatology · Pittsburgh, PANPI 1356316004
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $33,870 of the $37,949 with a category attached, or 89.3%. 9 manufacturers reported payments, led by Boehringer Ingelheim at 37.9% of the total. 2025 is the largest year on record at $21,809, more than ten times the $40 reported in 2019.
Across 27 payments — averaging $1405.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$14K
- Pfizer$9K
- Boehringer Ingelheim International GmbH$7K
- Astellas Pharma Inc$3K
- AstraZeneca$2K
- EMD Serono, Inc.$2K
- plus $365 from 3 others
Across 24 payments — averaging $25,352 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$296K
- EMD Serono, Inc.$111K
- E.r. Squibb & Sons, L.L.C.$76K
- EMD Serono Research & Development Institute, Inc.$42K
- AstraZeneca$32K
- Pfizer$26K
- plus $26K from 2 others
What the payments were for
- Consulting fees$33,87089%
- Speaking & faculty fees$2,6537%
- Travel & lodging$1,1103%
- Food & beverage$3161%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 12 | $14,394 |
| Pfizer | 5 | $8,910 |
| Boehringer Ingelheim International GmbH | 2 | $6,820 |
| Astellas Pharma Inc | 2 | $3,360 |
| AstraZeneca | 1 | $2,100 |
| EMD Serono, Inc. | 1 | $2,000 |
| Cardinal Health 110 LLC | 2 | $200 |
| AbbVie | 1 | $125 |
| GSK | 1 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,949 in reported general payments places this provider in the 85th percentile of 351 rheumatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 107 | $772,340 |
| Humira(Cf) PenAdalimumab | 53 | $384,313 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 69 | $346,327 |
| EnbrelEtanercept | 30 | $219,448 |
| Xeljanz XrTofacitinib Citrate | 28 | $164,131 |
| Orencia ClickjectAbatacept | 26 | $148,162 |
| BenlystaBelimumab | 18 | $125,401 |
| Cosentyx Sensoready PenSecukinumab | 13 | $94,197 |
| MethotrexateMethotrexate Sodium | 339 | $10,899 |
| Mycophenolate Mofetil | 57 | $7,296 |
| Cevimeline Hcl | 28 | $6,960 |
| Hydroxychloroquine Sulfate | 167 | $6,090 |
| Prednisone | 430 | $2,753 |
| PrografTacrolimus | 12 | $2,352 |
| Leflunomide | 42 | $1,275 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBenlysta | $40 | $125,40118 claims |
| Astellas Pharma IncPrograf | $3,360 | $2,35212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 351 rheumatology providers in Pennsylvania.
Other rheumatology in Pittsburgh
- Rohit AggarwalPittsburgh$810K
- Susan ManziPittsburgh$67K
- Michael LuckePittsburgh$51K
- Daniella SchwartzPittsburgh$38K
- Lindsay LedwichPittsburgh$37K
- Robyn DomsicPittsburgh$28K
- Ghassan AlayliPittsburgh$24K
- Tanmayee BichilePittsburgh$24K
- Alan EpsteinPhiladelphia$1.2M
- Lawrence LeventhalHuntingdon Valley$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.